Copyright Reports & Markets. All rights reserved.

Global Long-acting Reversible Contraceptives (LARCs) Market Research Report 2022

Request for Sample of this report
Buy now

Table of Contents

    1 Long-acting Reversible Contraceptives (LARCs) Market Overview

    • 1.1 Product Overview and Scope of Long-acting Reversible Contraceptives (LARCs)
    • 1.2 Long-acting Reversible Contraceptives (LARCs) Segment by Type
      • 1.2.1 Global Long-acting Reversible Contraceptives (LARCs) Sales Growth Rate Comparison by Type (2022-2028)
      • 1.2.2 Hormonal Intrauterine Devices
      • 1.2.3 Copper Intrauterine Devices
      • 1.2.4 Contraceptive Implants
      • 1.2.5 Others
    • 1.3 Long-acting Reversible Contraceptives (LARCs) Segment by Application
      • 1.3.1 Global Long-acting Reversible Contraceptives (LARCs) Sales Comparison by Application: (2022-2028)
      • 1.3.2 Age 20-24
      • 1.3.3 Age 25-34
      • 1.3.4 Age 35-44
      • 1.3.5 Others
    • 1.4 Global Long-acting Reversible Contraceptives (LARCs) Market Size Estimates and Forecasts
      • 1.4.1 Global Long-acting Reversible Contraceptives (LARCs) Revenue 2017-2028
      • 1.4.2 Global Long-acting Reversible Contraceptives (LARCs) Sales 2017-2028
      • 1.4.3 Long-acting Reversible Contraceptives (LARCs) Market Size by Region: 2017 Versus 2021 Versus 2028

    2 Long-acting Reversible Contraceptives (LARCs) Market Competition by Manufacturers

    • 2.1 Global Long-acting Reversible Contraceptives (LARCs) Sales Market Share by Manufacturers (2017-2022)
    • 2.2 Global Long-acting Reversible Contraceptives (LARCs) Revenue Market Share by Manufacturers (2017-2022)
    • 2.3 Global Long-acting Reversible Contraceptives (LARCs) Average Price by Manufacturers (2017-2022)
    • 2.4 Manufacturers Long-acting Reversible Contraceptives (LARCs) Manufacturing Sites, Area Served, Product Type
    • 2.5 Long-acting Reversible Contraceptives (LARCs) Market Competitive Situation and Trends
      • 2.5.1 Long-acting Reversible Contraceptives (LARCs) Market Concentration Rate
      • 2.5.2 The Global Top 5 and Top 10 Largest Long-acting Reversible Contraceptives (LARCs) Players Market Share by Revenue
      • 2.5.3 Global Long-acting Reversible Contraceptives (LARCs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

    3 Long-acting Reversible Contraceptives (LARCs) Retrospective Market Scenario by Region

    • 3.1 Global Long-acting Reversible Contraceptives (LARCs) Retrospective Market Scenario in Sales by Region: 2017-2022
    • 3.2 Global Long-acting Reversible Contraceptives (LARCs) Retrospective Market Scenario in Revenue by Region: 2017-2022
    • 3.3 North America Long-acting Reversible Contraceptives (LARCs) Market Facts & Figures by Country
      • 3.3.1 North America Long-acting Reversible Contraceptives (LARCs) Sales by Country
      • 3.3.2 North America Long-acting Reversible Contraceptives (LARCs) Revenue by Country
      • 3.3.3 United States
      • 3.3.4 Canada
    • 3.4 Europe Long-acting Reversible Contraceptives (LARCs) Market Facts & Figures by Country
      • 3.4.1 Europe Long-acting Reversible Contraceptives (LARCs) Sales by Country
      • 3.4.2 Europe Long-acting Reversible Contraceptives (LARCs) Revenue by Country
      • 3.4.3 Germany
      • 3.4.4 France
      • 3.4.5 U.K.
      • 3.4.6 Italy
      • 3.4.7 Russia
    • 3.5 Asia Pacific Long-acting Reversible Contraceptives (LARCs) Market Facts & Figures by Region
      • 3.5.1 Asia Pacific Long-acting Reversible Contraceptives (LARCs) Sales by Region
      • 3.5.2 Asia Pacific Long-acting Reversible Contraceptives (LARCs) Revenue by Region
      • 3.5.3 China
      • 3.5.4 Japan
      • 3.5.5 South Korea
      • 3.5.6 India
      • 3.5.7 Australia
      • 3.5.8 China Taiwan
      • 3.5.9 Indonesia
      • 3.5.10 Thailand
      • 3.5.11 Malaysia
    • 3.6 Latin America Long-acting Reversible Contraceptives (LARCs) Market Facts & Figures by Country
      • 3.6.1 Latin America Long-acting Reversible Contraceptives (LARCs) Sales by Country
      • 3.6.2 Latin America Long-acting Reversible Contraceptives (LARCs) Revenue by Country
      • 3.6.3 Mexico
      • 3.6.4 Brazil
      • 3.6.5 Argentina
    • 3.7 Middle East and Africa Long-acting Reversible Contraceptives (LARCs) Market Facts & Figures by Country
      • 3.7.1 Middle East and Africa Long-acting Reversible Contraceptives (LARCs) Sales by Country
      • 3.7.2 Middle East and Africa Long-acting Reversible Contraceptives (LARCs) Revenue by Country
      • 3.7.3 Turkey
      • 3.7.4 Saudi Arabia
      • 3.7.5 UAE

    4 Global Long-acting Reversible Contraceptives (LARCs) Historic Market Analysis by Type

    • 4.1 Global Long-acting Reversible Contraceptives (LARCs) Sales Market Share by Type (2017-2022)
    • 4.2 Global Long-acting Reversible Contraceptives (LARCs) Revenue Market Share by Type (2017-2022)
    • 4.3 Global Long-acting Reversible Contraceptives (LARCs) Price by Type (2017-2022)

    5 Global Long-acting Reversible Contraceptives (LARCs) Historic Market Analysis by Application

    • 5.1 Global Long-acting Reversible Contraceptives (LARCs) Sales Market Share by Application (2017-2022)
    • 5.2 Global Long-acting Reversible Contraceptives (LARCs) Revenue Market Share by Application (2017-2022)
    • 5.3 Global Long-acting Reversible Contraceptives (LARCs) Price by Application (2017-2022)

    6 Key Companies Profiled

    • 6.1 Bayer
      • 6.1.1 Bayer Corporation Information
      • 6.1.2 Bayer Description and Business Overview
      • 6.1.3 Bayer Long-acting Reversible Contraceptives (LARCs) Sales, Revenue and Gross Margin (2017-2022)
      • 6.1.4 Bayer Long-acting Reversible Contraceptives (LARCs) Product Portfolio
      • 6.1.5 Bayer Recent Developments/Updates
    • 6.2 Merck
      • 6.2.1 Merck Corporation Information
      • 6.2.2 Merck Description and Business Overview
      • 6.2.3 Merck Long-acting Reversible Contraceptives (LARCs) Sales, Revenue and Gross Margin (2017-2022)
      • 6.2.4 Merck Long-acting Reversible Contraceptives (LARCs) Product Portfolio
      • 6.2.5 Merck Recent Developments/Updates
    • 6.3 Cooper Companies
      • 6.3.1 Cooper Companies Corporation Information
      • 6.3.2 Cooper Companies Description and Business Overview
      • 6.3.3 Cooper Companies Long-acting Reversible Contraceptives (LARCs) Sales, Revenue and Gross Margin (2017-2022)
      • 6.3.4 Cooper Companies Long-acting Reversible Contraceptives (LARCs) Product Portfolio
      • 6.3.5 Cooper Companies Recent Developments/Updates
    • 6.4 AbbVie Allergan
      • 6.4.1 AbbVie Allergan Corporation Information
      • 6.4.2 AbbVie Allergan Description and Business Overview
      • 6.4.3 AbbVie Allergan Long-acting Reversible Contraceptives (LARCs) Sales, Revenue and Gross Margin (2017-2022)
      • 6.4.4 AbbVie Allergan Long-acting Reversible Contraceptives (LARCs) Product Portfolio
      • 6.4.5 AbbVie Allergan Recent Developments/Updates
    • 6.5 Yantai JiShengYaoXie
      • 6.5.1 Yantai JiShengYaoXie Corporation Information
      • 6.5.2 Yantai JiShengYaoXie Description and Business Overview
      • 6.5.3 Yantai JiShengYaoXie Long-acting Reversible Contraceptives (LARCs) Sales, Revenue and Gross Margin (2017-2022)
      • 6.5.4 Yantai JiShengYaoXie Long-acting Reversible Contraceptives (LARCs) Product Portfolio
      • 6.5.5 Yantai JiShengYaoXie Recent Developments/Updates
    • 6.6 H & J Medical
      • 6.6.1 H & J Medical Corporation Information
      • 6.6.2 H & J Medical Description and Business Overview
      • 6.6.3 H & J Medical Long-acting Reversible Contraceptives (LARCs) Sales, Revenue and Gross Margin (2017-2022)
      • 6.6.4 H & J Medical Long-acting Reversible Contraceptives (LARCs) Product Portfolio
      • 6.6.5 H & J Medical Recent Developments/Updates
    • 6.7 HRA Pharma
      • 6.6.1 HRA Pharma Corporation Information
      • 6.6.2 HRA Pharma Description and Business Overview
      • 6.6.3 HRA Pharma Long-acting Reversible Contraceptives (LARCs) Sales, Revenue and Gross Margin (2017-2022)
      • 6.4.4 HRA Pharma Long-acting Reversible Contraceptives (LARCs) Product Portfolio
      • 6.7.5 HRA Pharma Recent Developments/Updates
    • 6.8 Pregna
      • 6.8.1 Pregna Corporation Information
      • 6.8.2 Pregna Description and Business Overview
      • 6.8.3 Pregna Long-acting Reversible Contraceptives (LARCs) Sales, Revenue and Gross Margin (2017-2022)
      • 6.8.4 Pregna Long-acting Reversible Contraceptives (LARCs) Product Portfolio
      • 6.8.5 Pregna Recent Developments/Updates
    • 6.9 ASPIVIX
      • 6.9.1 ASPIVIX Corporation Information
      • 6.9.2 ASPIVIX Description and Business Overview
      • 6.9.3 ASPIVIX Long-acting Reversible Contraceptives (LARCs) Sales, Revenue and Gross Margin (2017-2022)
      • 6.9.4 ASPIVIX Long-acting Reversible Contraceptives (LARCs) Product Portfolio
      • 6.9.5 ASPIVIX Recent Developments/Updates
    • 6.10 Shanghai Dahua Pharmaceuticals
      • 6.10.1 Shanghai Dahua Pharmaceuticals Corporation Information
      • 6.10.2 Shanghai Dahua Pharmaceuticals Description and Business Overview
      • 6.10.3 Shanghai Dahua Pharmaceuticals Long-acting Reversible Contraceptives (LARCs) Sales, Revenue and Gross Margin (2017-2022)
      • 6.10.4 Shanghai Dahua Pharmaceuticals Long-acting Reversible Contraceptives (LARCs) Product Portfolio
      • 6.10.5 Shanghai Dahua Pharmaceuticals Recent Developments/Updates
    • 6.11 Williams Medical Supplies
      • 6.11.1 Williams Medical Supplies Corporation Information
      • 6.11.2 Williams Medical Supplies Long-acting Reversible Contraceptives (LARCs) Description and Business Overview
      • 6.11.3 Williams Medical Supplies Long-acting Reversible Contraceptives (LARCs) Sales, Revenue and Gross Margin (2017-2022)
      • 6.11.4 Williams Medical Supplies Long-acting Reversible Contraceptives (LARCs) Product Portfolio
      • 6.11.5 Williams Medical Supplies Recent Developments/Updates
    • 6.12 Laboratoire 7 MED
      • 6.12.1 Laboratoire 7 MED Corporation Information
      • 6.12.2 Laboratoire 7 MED Long-acting Reversible Contraceptives (LARCs) Description and Business Overview
      • 6.12.3 Laboratoire 7 MED Long-acting Reversible Contraceptives (LARCs) Sales, Revenue and Gross Margin (2017-2022)
      • 6.12.4 Laboratoire 7 MED Long-acting Reversible Contraceptives (LARCs) Product Portfolio
      • 6.12.5 Laboratoire 7 MED Recent Developments/Updates
    • 6.13 Durbin
      • 6.13.1 Durbin Corporation Information
      • 6.13.2 Durbin Long-acting Reversible Contraceptives (LARCs) Description and Business Overview
      • 6.13.3 Durbin Long-acting Reversible Contraceptives (LARCs) Sales, Revenue and Gross Margin (2017-2022)
      • 6.13.4 Durbin Long-acting Reversible Contraceptives (LARCs) Product Portfolio
      • 6.13.5 Durbin Recent Developments/Updates
    • 6.14 Laboratoire CCD
      • 6.14.1 Laboratoire CCD Corporation Information
      • 6.14.2 Laboratoire CCD Long-acting Reversible Contraceptives (LARCs) Description and Business Overview
      • 6.14.3 Laboratoire CCD Long-acting Reversible Contraceptives (LARCs) Sales, Revenue and Gross Margin (2017-2022)
      • 6.14.4 Laboratoire CCD Long-acting Reversible Contraceptives (LARCs) Product Portfolio
      • 6.14.5 Laboratoire CCD Recent Developments/Updates
    • 6.15 Prosan
      • 6.15.1 Prosan Corporation Information
      • 6.15.2 Prosan Long-acting Reversible Contraceptives (LARCs) Description and Business Overview
      • 6.15.3 Prosan Long-acting Reversible Contraceptives (LARCs) Sales, Revenue and Gross Margin (2017-2022)
      • 6.15.4 Prosan Long-acting Reversible Contraceptives (LARCs) Product Portfolio
      • 6.15.5 Prosan Recent Developments/Updates
    • 6.16 OCON
      • 6.16.1 OCON Corporation Information
      • 6.16.2 OCON Long-acting Reversible Contraceptives (LARCs) Description and Business Overview
      • 6.16.3 OCON Long-acting Reversible Contraceptives (LARCs) Sales, Revenue and Gross Margin (2017-2022)
      • 6.16.4 OCON Long-acting Reversible Contraceptives (LARCs) Product Portfolio
      • 6.16.5 OCON Recent Developments/Updates

    7 Long-acting Reversible Contraceptives (LARCs) Manufacturing Cost Analysis

    • 7.1 Long-acting Reversible Contraceptives (LARCs) Key Raw Materials Analysis
      • 7.1.1 Key Raw Materials
      • 7.1.2 Key Suppliers of Raw Materials
    • 7.2 Proportion of Manufacturing Cost Structure
    • 7.3 Manufacturing Process Analysis of Long-acting Reversible Contraceptives (LARCs)
    • 7.4 Long-acting Reversible Contraceptives (LARCs) Industrial Chain Analysis

    8 Marketing Channel, Distributors and Customers

    • 8.1 Marketing Channel
    • 8.2 Long-acting Reversible Contraceptives (LARCs) Distributors List
    • 8.3 Long-acting Reversible Contraceptives (LARCs) Customers

    9 Long-acting Reversible Contraceptives (LARCs) Market Dynamics

    • 9.1 Long-acting Reversible Contraceptives (LARCs) Industry Trends
    • 9.2 Long-acting Reversible Contraceptives (LARCs) Market Drivers
    • 9.3 Long-acting Reversible Contraceptives (LARCs) Market Challenges
    • 9.4 Long-acting Reversible Contraceptives (LARCs) Market Restraints

    10 Global Market Forecast

    • 10.1 Long-acting Reversible Contraceptives (LARCs) Market Estimates and Projections by Type
      • 10.1.1 Global Forecasted Sales of Long-acting Reversible Contraceptives (LARCs) by Type (2023-2028)
      • 10.1.2 Global Forecasted Revenue of Long-acting Reversible Contraceptives (LARCs) by Type (2023-2028)
    • 10.2 Long-acting Reversible Contraceptives (LARCs) Market Estimates and Projections by Application
      • 10.2.1 Global Forecasted Sales of Long-acting Reversible Contraceptives (LARCs) by Application (2023-2028)
      • 10.2.2 Global Forecasted Revenue of Long-acting Reversible Contraceptives (LARCs) by Application (2023-2028)
    • 10.3 Long-acting Reversible Contraceptives (LARCs) Market Estimates and Projections by Region
      • 10.3.1 Global Forecasted Sales of Long-acting Reversible Contraceptives (LARCs) by Region (2023-2028)
      • 10.3.2 Global Forecasted Revenue of Long-acting Reversible Contraceptives (LARCs) by Region (2023-2028)

    11 Research Finding and Conclusion

      12 Methodology and Data Source

      • 12.1 Methodology/Research Approach
        • 12.1.1 Research Programs/Design
        • 12.1.2 Market Size Estimation
        • 12.1.3 Market Breakdown and Data Triangulation
      • 12.2 Data Source
        • 12.2.1 Secondary Sources
        • 12.2.2 Primary Sources
      • 12.3 Author List

      Summary:

      Industry Insights
      Due to the COVID-19 pandemic, the global Long-acting Reversible Contraceptives (LARCs) market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Long-acting Reversible Contraceptives (LARCs) market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Long-acting Reversible Contraceptives (LARCs) landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
      Hormonal Intrauterine Devices accounting for % of the Long-acting Reversible Contraceptives (LARCs) global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Age 20-24 segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
      The global major manufacturers of Long-acting Reversible Contraceptives (LARCs) include Bayer, Merck, Cooper Companies, AbbVie Allergan, Yantai JiShengYaoXie, H & J Medical, HRA Pharma, Pregna and ASPIVIX, etc. In terms of revenue, the global 3 largest players have a % market share of Long-acting Reversible Contraceptives (LARCs) in 2021.
      This report focuses on Long-acting Reversible Contraceptives (LARCs) volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Long-acting Reversible Contraceptives (LARCs) market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
      Key Drivers & Barriers
      High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
      Post-covid-19 Outlook
      The readers in the section will understand how the Long-acting Reversible Contraceptives (LARCs) market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
      Segmental Outlook
      Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).
      Segment by Type
      Hormonal Intrauterine Devices
      Copper Intrauterine Devices
      Contraceptive Implants
      Others
      Segment by Application
      Age 20-24
      Age 25-34
      Age 35-44
      Others
      Regional Outlook
      This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.
      North America
      United States
      Canada
      Europe
      Germany
      France
      U.K.
      Italy
      Russia
      Asia-Pacific
      China
      Japan
      South Korea
      India
      Australia
      China Taiwan
      Indonesia
      Thailand
      Malaysia
      Latin America
      Mexico
      Brazil
      Argentina
      Middle East & Africa
      Turkey
      Saudi Arabia
      UAE
      Competitive Scenario
      In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
      Bayer
      Merck
      Cooper Companies
      AbbVie Allergan
      Yantai JiShengYaoXie
      H & J Medical
      HRA Pharma
      Pregna
      ASPIVIX
      Shanghai Dahua Pharmaceuticals
      Williams Medical Supplies
      Laboratoire 7 MED
      Durbin
      Laboratoire CCD
      Prosan
      OCON
      Frequently Asked Questions
      Which product segment grabbed the largest share in the Long-acting Reversible Contraceptives (LARCs) market?
      How is the competitive scenario of the Long-acting Reversible Contraceptives (LARCs) market?
      Which are the key factors aiding the Long-acting Reversible Contraceptives (LARCs) market growth?
      Which are the prominent players in the Long-acting Reversible Contraceptives (LARCs) market?
      Which region holds the maximum share in the Long-acting Reversible Contraceptives (LARCs) market?
      What will be the CAGR of the Long-acting Reversible Contraceptives (LARCs) market during the forecast period?
      Which application segment emerged as the leading segment in the Long-acting Reversible Contraceptives (LARCs) market?
      What key trends are likely to emerge in the Long-acting Reversible Contraceptives (LARCs) market in the coming years?
      What will be the Long-acting Reversible Contraceptives (LARCs) market size by 2028?
      Which company held the largest share in the Long-acting Reversible Contraceptives (LARCs) market?
      Buy now